BioSpace News Archive

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced that Duet Therapeutics, a wholly-owned subsidiary of Scopus, will release scientific data during the 17th Annual Meeting of the Oligonucleotide Therapeutics Society.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific and investor conferences in October:

Merck, known as MSD outside the United States and Canada, will hold its third-quarter 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, October 28.

Silence Therapeutics plc announced that the Company will participate in a fireside chat at the Chardan Virtual Genetic Medicines Conference on Tuesday, October 5th at 8:30 a.m.

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced the receipt of a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas.

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi as shareholders, announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for a New Drug Application for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP.

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo ®

Veeva Systems announced Veeva Vault LIMS, a new cloud application to modernize quality control lab operations.

Athersys, Inc. (NASDAQ: ATHX) announced today that a Conference is being held Oct. 12th to 14th, 2021 in Carlsbad

SAB Biotherapeutics today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021.